Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by jakethesnake2on May 14, 2014 3:17pm
361 Views
Post# 22561885

RE:RE:4050

RE:RE:4050
Bob,
I was at the AGM and the person that asked the question was right next to me.
Dr Moran presentation was only on PBI 4050 and he mentioned during his presentation that the 7 and 8 patient in the world received PBI 4050 today in Quebec City.
The question was asked to see if 4050 was really being used on patients and Pierre jumped in to correct Dr.Moran and said that it was being tested on healthy volunteer humans and not patients but that it would be tested with patients later on in Phase 1

Hope this does not confuse you even more.lol
Regards
Jack
Bullboard Posts